137
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study

, , &
Pages 107-116 | Published online: 14 Oct 2016

References

  • MuradKKitzmanDWFrailty and multiple comorbidities in the elderly patient with heart failure: implications for managementHeart Fail Rev2012174–558158821626426
  • RussoCAElixhauserAHospitalizations in the Elderly Population, 2003Statistical Brief #652006Agency for Healthcare Research and QualityRockville, MD Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb6.jspAccessed October 4, 2016
  • FillenbaumGGPieperCFCohenHJCornoni-HuntleyJCGuralnikJMComorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortalityJ Gerontol A Biol Sci Med Sci2000552M84M8910737690
  • FranchiCNobiliAMariDREPOSI InvestigatorsRisk factors for hospital readmission of elderly patientsEur J Intern Med2013241455123142413
  • MaherRLHanlonJHajjarERClinical consequences of polypharmacy in elderlyExpert Opin Drug Saf2014131576524073682
  • SlabaughSLMaioVTemplinMAbouzaidSPrevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, ItalyDrugs Aging201027121019102821087071
  • SgangaFLandiFRuggieroCPolypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME studyGeriatr Gerontol Int201515214114624467719
  • MarcumZAAmuanMEHanlonJTAspinallSLHandlerSMRubyCMPughMJPrevalence of unplanned hospitalizations caused by adverse drug reactions in older veteransJ Am Geriatr Soc2012601344122150441
  • SaldivarJSTaylorDSugarmanEACullorsAGarcesJAOadesKCentenoJInitial assessment of the benefits of implementing pharma-cogenetics into the medical management of patients in a long-term care facilityPharmgenomics Pers Med201691626855597
  • HiratsukaMSasakiTMizugakiMGenetic testing for pharmaco-genetics and its clinical application in drug therapyClin Chim Acta20063631–217718616126184
  • OetjensMTDennyJCRitchieMDAssessment of a pharma-cogenomic marker panel in a polypharmacy population identified from electronic medical recordsPharmacogenomics201314773574423651022
  • LeederJSPharmacogenetics and pharmacogenomicsPediatr Clin North Am200148376578111411304
  • LiJBluthMHPharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapyPharmgenomics Pers Med20114113323226051
  • WijnenPAOp den BuijschRADrentMReview article: the prevalence and clinical relevance of cytochrome P450 polymorphismsAliment Pharmacol Ther200726Suppl 221121918081664
  • CavallariLHJeongHBressARole of cytochrome P450 genotype in the steps toward personalized drug therapyPharmgenomics Pers Med2011412313623226058
  • García-GonzálezXCabaleiroTHerreroMJMcLeodHLópez-FernándezLAClinical implementation of pharmacogeneticsDrug Metab Pers Ther201631191626751902
  • SehrtDMeinekeITzvetkovMGültepeGBrockmöllerJCarvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogeneticsPharmacogenomics201112678379521599570
  • BrownJTAbdel-RahmanSMvan HaandelLGaedigkALinYSLeederJSSingle dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHDClin Pharmacol Ther201699664265026660002
  • SimSCIngelman-SundbergMPharmacogenomic biomarkers: new tools in current and future drug therapyTrends Pharmacol Sci2011322728121185092
  • StergiopoulosKBrownDLGenotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trialsJAMA Intern Med201417481330133824935087
  • FinkelsteinJFriedmanCHripcsakGCabreraMPotential utility of precision medicine for older adults with polypharmacy: a case series studyPharmgenomics Pers Med20169314527143951
  • ChaudhrySIMcAvayGChenSWhitsonHNewmanABKrumholzHMGillTMRisk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health StudyJ Am Coll Cardiol201361663564223391194
  • BrixnerDBiltajiEBressAThe effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacyJ Med Econ201619321322826478982
  • FortinskyRHMadiganEASheehanTJTullai-McGuinnessSKlep-pingerARisk factors for hospitalization in a national sample of medicare home health care patientsJ Appl Gerontol201433447449324781967
  • Von KorffMWagnerEHSaundersKA chronic disease score from automated pharmacy dataJ Clin Epidemiol19924521972031573438
  • ClarkDOVon KorffMSaundersKBaluchWMSimonGEA chronic disease score with empirically derived weightsMed Care19953387837957637401
  • JohnsonREHornbrookMCNicholsGAReplicating the chronic disease score (CDS) from automated pharmacy dataJ Clin Epidemiol19944710119111997722553
  • SchneeweissSSeegerJDMaclureMWangPSAvornJGlynnRJPerformance of comorbidity scores to control for confounding in epidemio-logic studies using claims dataAm J Epidemiol2001154985486411682368
  • SchneeweissSMaclureMUse of comorbidity scores for control of confounding in studies using administrative databasesInt J Epidemiol200029589189811034974
  • MoriskyDEGreenLWLevineDMConcurrent and predictive validity of a self-reported measure of medication adherenceMed Care198624167743945130
  • FernandezSChaplinWSchoenthalerAMOgedegbeGRevision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African AmericansJ Behav Med200831645346218784996
  • NairNPChalmersLPetersonGMBereznickiBJCastelinoRLBer-eznickiLRHospitalization in older patients due to adverse drug reactions – the need for a prediction toolClin Interv Aging20161149750527194906
  • García-PérezLLinertováRLorenzo-RieraAVázquez-DíazJRDuque-GonzálezBSarría-SantameraARisk factors for hospital readmissions in elderly patients: a systematic reviewQJM2011104863965121558329
  • SeripaDParoniGUrbanoMSantiniSAD’OnofrioGPilottoAPharmacogenetics in older people: what we know and what we need to knowJ Nephrol201225Suppl 19S38S4722476963
  • SeripaDPanzaFDaragjatiJParoniGPilottoAMeasuring phar-macogenetics in special groups: geriatricsExpert Opin Drug Metab Toxicol20151171073108825990744
  • HohlCMDankoffJColaconeAAfilaloMPolypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency departmentAnn Emerg Med200138666667111719747
  • CampbellNLSkaarTCPerkinsAJGaoSLiLKhanBABoustaniMACharacterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapyClin Interv Aging20151026927525609939
  • BreslowNEDayNStatistical Methods in Cancer Epidemiology: Analysis of Case-Control StudiesILyon, FranceIARC Scientific Publications
  • WangYMcCulloughMLStevensVLNested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancerAnticancer Res2007271B58959317348446
  • ErnsterVLNested case-control studiesPrev Med19942355875907845919
  • QatoDMAlexanderGCContiRUse of prescription and over-the-counter medications and dietary supplements among older adults in the United StatesJAMA20083002867287819109115
  • SehgalVBajwaSJSehgalRBajajAKhairaUKresseVPolyphar-macy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospitalJ Fam Med Prim Care201322194199
  • Isidoro-GarcíaMSánchez-MartínAGarcía-BerrocalBRomán-CurtoCPrimun non nocere, polypharmacy and pharmacogeneticsPharmacogenomics201516171903190526554320
  • SalviFMarchettiAD’AngeloFBoemiMLattanzioFCherubiniAAdverse drug events as a cause of hospitalization in older adultsDrug Saf201235Suppl 1294523446784
  • MoxeyEDO’ConnorJPNovielliKDTeutschSNashDBPrescription drug use in the elderly: a descriptive analysisHealth Care Financ Rev200324412714114628405
  • NightingaleGHajjarESwartzKAndrel-SendeckiJChapmanAEvaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancerJ Clin Oncol201533131453145925800766
  • ShahRRGaedigkALLerenaAEichelbaumMStinglJSmithRLCYP450 genotype and pharmacogenetic association studies: a critical appraisalPharmacogenomics201617325927526780308
  • KlotzJSmall sample power and efficiency for the one sample Wilcoxon and normal scores testsAnn Math Statist1963342624632
  • FagerlandMWLydersenSLaakePThe McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditionalBMC Med Res Methodol2013139123848987
  • HoyleRStatistical Strategies for Small Sample ResearchNew YorkSAGE Publications1999
  • PettMANonparametric Statistics for Health Care Research: Statistics for Small Samples and Unusual DistributionsNew YorkSAGE Publications1997
  • De WinterJCFUsing the Student’s t-test with extremely small sample sizesPrac Assess Res Eval20131810112
  • WiggintonJCutlerDAbecasisGA note on exact tests of Hardy–Weinberg equilibriumAm J Hum Genet200576588789315789306
  • Gimeno-GraciaMCrusells-CanalesMJArmesto-GómezFJCom-paired-TurlánVRabanaque-HernándezMJPolypharmacy in older adults with human immunodeficiency virus infection compared with the general populationClin Interv Aging2016111149115727616883
  • HoltzmanCArmonCTedaldiEChmielJSBuchaczKWoodKBrooksJTthe HOPS InvestigatorsPolypharmacy and risk of anti-retroviral drug interactions among the aging HIV-infected populationJ Gen Intern Med201328101302131023605401
  • SirachainanEJaruhathaiSTrachuNCYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patientsPharmgenomics Pers Med2012514915323226070
  • WoopenHRichterRIsmaeelFChekerovRRootsISiepmannTSehouliJThe influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancerGynecol Oncol2016140355455826790772
  • FranssenFMSpruitMAWoutersEFDeterminants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2011649350122069360
  • CarpenterJSRosenmanMBKniselyMRDeckerBSLevyKDFlockhartDAPharmacogenomically actionable medications in a safety net health care systemSAGE Open Med20164205031211562433326835014